Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?
Clin Sci (Lond)
; 138(11): 687-697, 2024 Jun 05.
Article
en En
| MEDLINE
| ID: mdl-38835256
ABSTRACT
Endothelin A and B receptors, together with sodium-glucose cotransporter-2 (SGLT-2) channels are important targets in improving endothelial function and intervention with inhibitors has been the subject of multiple mechanistic and clinical outcome trials over recent years. Notable successes include the treatment of pulmonary hypertension with endothelin receptor antagonists, and the treatment of heart failure and chronic kidney disease with SGLT-2 inhibitors. With distinct and complementary mechanisms, in this review, we explore the logic of combination therapy for a number of diseases which have endothelial dysfunction at their heart.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Endotelio Vascular
/
Endotelina-1
/
Inhibidores del Cotransportador de Sodio-Glucosa 2
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Clin Sci (Lond)
Año:
2024
Tipo del documento:
Article
País de afiliación:
Suecia